Show simple item record

dc.contributor.authorMatias-Guiu, Jordi
dc.contributor.authorGonzález Rosa, Javier Jesús 
dc.contributor.authorHernández, Miguel Ángel
dc.contributor.authorMartínez-Ginés, Maria Luisa
dc.contributor.authorPortolés, Antonio
dc.contributor.authorPérez-Macías, Natalia
dc.contributor.authorBenito-León, Julián
dc.contributor.authorPadrón, Iván
dc.contributor.authorPrieto, Julio
dc.contributor.authorMatias-Guiu, Jorge
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2024-06-25T11:20:12Z
dc.date.available2024-06-25T11:20:12Z
dc.date.issued2024
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/10498/32753
dc.description.abstractIntroduction Fatigue is one of the most disabling symptoms of multiple sclerosis (MS), and effective treatments are lacking. Amantadine is one of the most used treatments, although its efficacy is under debate. Transcranial magnetic stimulation (TMS) is a promising intervention that has shown positive effects in some preliminary investigations. We aim to investigate the effect of 6 weeks of amantadine and/or TMS in fatigue due to MS. Methods and analysis The study is a national, multicentre, phase 3, randomised, double-blind, cross-over, placebo-controlled and sham-controlled clinical trial. Adult patients with relapsing-remitting MS, Expanded Disability Status Scale score of 1.5–4.5 and Fatigue Severity Score>4 are eligible for the trial. Participants will be randomised to one of the sequences of the study. Each sequence consists of four periods of 6 weeks of treatment and three washout periods of 12–18 weeks. All patients will receive all the combinations of therapies. The primary outcome is the Modified Fatigue Impact Scale. The secondary outcomes are the Symbol Digit Modalities Test (cognition), Beck Depression Inventory-II (depressive symptoms) and Short-Survey 12 (quality of life). Safety and cost-effectiveness will also be evaluated. An exploratory substudy including MRI and blood biomarkers will be conducted. Ethics and dissemination The study is approved by the Ethics Committee of the Hospital Clinico San Carlos and the Spanish Agency of Medications and Medical Devices. All study findings will be published in scientific peer-reviewed journals and presented at relevant scientific conferences.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceBMJ Open - 2024, Vol. 14 n.1es_ES
dc.titleAmantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical triales_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doihttps://doi.org/10.1136/BMJOPEN-2023-078661
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This work is under a Creative Commons License Atribución-NoComercial 4.0 Internacional